27 - 28 February 2023 | Manchester , UK

Isabella Gashaw

Principal Clinical Biomarker Lead Cardiometabolism
Boehringer Ingelheim
Isabella Gashaw
Isabella is passionate about developing translational concepts to improve effectiveness of drug development for better patient care. She builds on more than 14 years of experience in research and development in pharmaceutical industry ranging from target identification to post launch activities. She is currently a principal translational and clinical biomarker lead for cardiometabolic diseases at Boehringer Ingelheim. In this role, she creates biomarker concepts and steers their qualification including implementation of these concepts in advanced chronic liver diseases across drug development stages. Before joining BI in February 2021, Isabella was employed with Bayer AG as director biomarker strategist for non-oncologic diseases. She has also worked in preclinical research in gynecologic and hematologic conditions. Prior embarking on drug discovery, Isabella was investigating molecular mechanisms of reproductive disorders in an academic environment. Isabella holds a PhD in Clinical Pharmacology from the Humboldt University in Berlin (Germany).


No data was found

Other Speakers

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.